KR910016734A - 광학활성 알킬렌디옥시벤젠 유도체 및 치료에의 용도 - Google Patents
광학활성 알킬렌디옥시벤젠 유도체 및 치료에의 용도 Download PDFInfo
- Publication number
- KR910016734A KR910016734A KR1019910003908A KR910003908A KR910016734A KR 910016734 A KR910016734 A KR 910016734A KR 1019910003908 A KR1019910003908 A KR 1019910003908A KR 910003908 A KR910003908 A KR 910003908A KR 910016734 A KR910016734 A KR 910016734A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- formula
- integer
- represented
- structural formula
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- GGNCUSDIUUCNKE-RSAXXLAASA-N 3-(1,3-benzodioxol-5-yloxy)-n-[[(3s)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine;hydrochloride Chemical compound Cl.C1=C2OCOC2=CC(OCCCNC[C@@H]2OC3=CC=CC=C3OC2)=C1 GGNCUSDIUUCNKE-RSAXXLAASA-N 0.000 claims 1
- JVTBXMRQZDQERY-LMOVPXPDSA-N 5-(1,3-benzodioxol-5-yloxy)-n-[[(3s)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]pentan-1-amine;hydrochloride Chemical compound Cl.C1=C2OCOC2=CC(OCCCCCNC[C@@H]2OC3=CC=CC=C3OC2)=C1 JVTBXMRQZDQERY-LMOVPXPDSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 230000000049 anti-anxiety effect Effects 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Anesthesiology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (13)
- 하기 구조식(Ⅰ)의 광학활성 알킬렌디옥시벤젠 유도체 및 그 산부가염.위의 식에서, m은 2~5의 정수이고, n은 1~3의 정수이다.
- 제1항에 있어서, 하기 구조식(I')으로 나타내어지는 화합물.위의 식에서 m과 n은 앞서 정의된 바와 같다.
- 제2항에 있어서, m이 3,4 또는 5의 정수인 화합물.
- 제3항에 있어서, n이 1인 화합물.
- 제4항에 있어서, 5-[3-{(2S)-(1,4-벤조디옥산-2-일메틸)아미노}프로폭시]-1,3-벤조디옥솔 염산염.
- 제4항에 있어서, 5-[4-{(2S)-(1,4-벤조디옥산-2-일메틸)아미노}부록시]-1,3-벤조디옥솔 염산염.
- 제4항에 있어서,5-[5-{(2S)-(1,4-벤조디옥산-2-일메틸)아미노}펜틸옥시] -1 ,3-벤조디옥솔 염산염.
- 적당한 부형제 또는 담체와 더불어 하기 일반 구조식(Ⅱ)의 화합물 또는 그 산부가염 유효량을 필수 성분으로 하여 함유하는 불안증 치료용 약제학적 조성물.위의 식에서 m과 n은 앞서 정의된 바와 같다.
- 제8항에 있어서, 화합물이 하기 구조식(Ⅱ')으로 나타내어 지는 것인 조성물.위의 식에서 m과 n은 앞서 정의된 바와 같다.
- 제9항에 있어서, 화합물이 구조식(Ⅱ')로 나타내어지는 것이고, m이 3,4 또는 5의 정수인 조성물.
- 제10항에 있어서, 화합물이 구조식(Ⅱ')로 나타내어지는 것이고, S배위를 하고 있는 것인 조성물.
- 제7항 또는 제 8항에서 정의된 화합물 또는 이들의 약제학적으로 허용 되는 염 유효량을 온혈동물에게 투여하는 온형동물의 불안증 치료방법.
- 제7항 또는 제 8항에서 정의된 화합물 또는 이들의 약제학적으로 허용 되는 염의 항불안 의약으로 유용한 약제학적 조성물 제조를 위한 용도.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2-63839 | 1990-03-14 | ||
JP2063839A JPH03264528A (ja) | 1990-03-14 | 1990-03-14 | 抗不安薬 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR910016734A true KR910016734A (ko) | 1991-11-05 |
KR100240242B1 KR100240242B1 (ko) | 2001-02-01 |
Family
ID=13240916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019910003908A KR100240242B1 (ko) | 1990-03-14 | 1991-03-12 | 광학활성 알킬렌디옥시벤젠 유도체 및 치료에의 용도 |
Country Status (10)
Country | Link |
---|---|
US (1) | US5168099A (ko) |
EP (1) | EP0446921B1 (ko) |
JP (1) | JPH03264528A (ko) |
KR (1) | KR100240242B1 (ko) |
AT (1) | ATE171704T1 (ko) |
CA (1) | CA2038025C (ko) |
DE (1) | DE69130266T2 (ko) |
DK (1) | DK0446921T3 (ko) |
ES (1) | ES2122962T3 (ko) |
TW (1) | TW200398B (ko) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5391570A (en) * | 1993-10-14 | 1995-02-21 | Bristol-Myers Squibb | Aminomethyl-benzodioxane and benzopyran serotonergic agents |
FR2716680B1 (fr) * | 1994-02-25 | 1996-04-05 | Adir | Nouveaux dérivés de benzodioxane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
US5525347A (en) * | 1995-01-31 | 1996-06-11 | Medical University Of South Carolina | Composition and methods for treating performance anxiety |
US5998467A (en) * | 1995-10-25 | 1999-12-07 | Mitsubishi Chemical Corporation | Medicine for oculopathy |
DE69807586T2 (de) * | 1997-05-20 | 2003-06-26 | Mitsubishi Chem Corp | Verwendung eines Alkylendioxybenzolderivats zur Behandlung von zirkadianen Schlafstörungen |
ES2218845T3 (es) * | 1997-08-19 | 2004-11-16 | Mitsubishi Chemical Corporation | Medicamentos para el sindrome del intestino irritable. |
CA2520813C (en) * | 2003-04-25 | 2009-10-27 | Mitsubishi Pharma Corporation | Sustained release formulations of alkylene dioxybenzene derivatives useful as 5-ht1a agonists |
CN101619059B (zh) * | 2008-07-01 | 2011-09-14 | 江苏恩华药业股份有限公司 | 盐酸奥沙莫唑坦的制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL281245A (ko) * | 1962-07-20 | |||
BE759468A (fr) * | 1969-11-27 | 1971-05-26 | Merck Patent Gmbh | Derives de benzodioxanne |
US4684739A (en) * | 1980-12-15 | 1987-08-04 | Mitsubishi Chemical Industries Limited | Alkylenedioxybenzene derivatives and acid addition salts thereof |
-
1990
- 1990-03-14 JP JP2063839A patent/JPH03264528A/ja active Pending
-
1991
- 1991-03-12 KR KR1019910003908A patent/KR100240242B1/ko not_active IP Right Cessation
- 1991-03-12 CA CA002038025A patent/CA2038025C/en not_active Expired - Fee Related
- 1991-03-14 DK DK91103944T patent/DK0446921T3/da active
- 1991-03-14 AT AT91103944T patent/ATE171704T1/de not_active IP Right Cessation
- 1991-03-14 ES ES91103944T patent/ES2122962T3/es not_active Expired - Lifetime
- 1991-03-14 DE DE69130266T patent/DE69130266T2/de not_active Expired - Fee Related
- 1991-03-14 US US07/668,480 patent/US5168099A/en not_active Expired - Lifetime
- 1991-03-14 EP EP91103944A patent/EP0446921B1/en not_active Expired - Lifetime
- 1991-03-28 TW TW080102458A patent/TW200398B/zh active
Also Published As
Publication number | Publication date |
---|---|
ATE171704T1 (de) | 1998-10-15 |
KR100240242B1 (ko) | 2001-02-01 |
DK0446921T3 (da) | 1999-06-21 |
ES2122962T3 (es) | 1999-01-01 |
DE69130266T2 (de) | 1999-03-18 |
DE69130266D1 (de) | 1998-11-05 |
JPH03264528A (ja) | 1991-11-25 |
US5168099A (en) | 1992-12-01 |
TW200398B (ko) | 1993-02-21 |
CA2038025A1 (en) | 1991-09-15 |
EP0446921A2 (en) | 1991-09-18 |
EP0446921A3 (en) | 1992-01-29 |
EP0446921B1 (en) | 1998-09-30 |
CA2038025C (en) | 2005-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR940006590A (ko) | 알쯔하이머 질환 치료용 및 혈당저하제로서 유용한 화합물 | |
KR900014367A (ko) | 피롤리딘 유도체 | |
OA09039A (fr) | Acides 3-alcenyl-1-azabicyclo(3.2.0)hep-2-ene-2carboxyliques | |
KR900006318A (ko) | 피페리디닐 벤즈이미다졸 | |
KR900007837A (ko) | 퀴누클리딘, 약제로서 이의 용도 및 이의 제조방법 | |
ATE38834T1 (de) | 5-substituierte 1,2,4-oxadiazol-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
KR870007160A (ko) | 신규의 디하이드로벤조푸란-및 크로만-카복스아미드 유도체, 그것의 제조 방법 및 신경이완제로서의 사용법 | |
KR910016734A (ko) | 광학활성 알킬렌디옥시벤젠 유도체 및 치료에의 용도 | |
KR910000630A (ko) | 할로겐 치환 디페닐 설파이드, 이의 제조방법 및 우울증 치료제로서의 용도 | |
DE3773017D1 (de) | Nicorandil enthaltende zubereitung zum einspritzen. | |
KR900014406A (ko) | 세펨 화합물 및 이의 제조방법 | |
KR900001715A (ko) | Bu-3608 유도체 | |
KR840006985A (ko) | N-치환플라본-8-카르복사미드유도체 및 그 제조방법 | |
KR910004557A (ko) | 2,4,6-치환 페놀 유도체 | |
PT92047A (pt) | Processo para a preparacao de derivados de nitroxialquilaminas com a funcao amida, de compostos intermediarios e de composicoes farmaceuticas que as contem | |
ATE18221T1 (de) | (1-arylcyclobutyl)(heterocyclyl)methylaminderivate, ihre herstellung und ihre verwendung als arzneimittel. | |
KR890012942A (ko) | 5-치환된 오르니틴 유도체 | |
EA199900510A1 (ru) | Инъекционное лекарственное средство "цитофлавин", обладающее цитопротекторным действием | |
KR850000415A (ko) | 퀴나졸리논 유도체의 제조방법 | |
KR940021524A (ko) | 1,2,5,6-테트라하이드로피리딘 유도체와 이의 제조 방법 및 치료시 이의 이용방법 | |
KR890002079A (ko) | 1-[2-(페닐메틸)페닐]피페라진 및 그의 제조방법 | |
KR910011815A (ko) | 티아졸릴-5-카본아미드 유도체 및 그의 제조방법 | |
KR920002594A (ko) | 5-이소티아졸아민 유도체 | |
KR830006229A (ko) | 이미다졸 유도체의 제조방법 | |
KR880001630A (ko) | 5-플루오로우라실 유도체 및 그의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 19981228 Effective date: 19990710 |
|
S901 | Examination by remand of revocation | ||
GRNO | Decision to grant (after opposition) | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20081010 Year of fee payment: 10 |
|
LAPS | Lapse due to unpaid annual fee |